Mineralys Therapeutics Submits New Drug Application for Hypertension Treatment Lorundrostat, Backed by Strong Clinical Data
Clinical-stage biopharma Mineralys Therapeutics has filed its New Drug Application for lorundrostat, a potential treatment for resistant hypertension, following positive results from multiple trials. The move positions the company for a potential 2026 market entry and has drawn upgraded price targets from analysts.